Alfit Injection (Cimetropium Bromide)

Adult administration

(Tablets) Adults: Administer 50 mg of cimetropium bromide per dose 2 ∼ 3 times daily. (Injection) 1. Gastrointestinal spasms accompanied by irritable bowel pain: Inject 5 mg of cimetropium bromide per dose intramuscularly or intravenously. 2. Premedication before examination: Administer 10 mg of this drug per dose by intravenous injection over at least 40 minutes.

If this drug is in a vial form, care must be taken when opening the container to avoid contamination with glass fragments. Extra caution is required when administering to children or the elderly. Individuals allergic to any active ingredient or other components of this drug should not use it. Furthermore, this drug should not be used by patients with benign prostatic hyperplasia, glaucoma, urinary retention, gastrointestinal tract obstruction, paralytic ileus, ulcerative colitis, megacolon, gastroesophageal reflux disease, or myasthenia gravis. Patients with autonomic nervous system disorders, liver or kidney diseases, chronic obstructive pulmonary disease, hyperthyroidism, coronary artery disease, congestive heart failure, arrhythmia, hypertension, or anomalous hyperthermia should use this drug cautiously. Especially, when administered as an injection, abdominal pain should be assessed to rule out myocardial infarction. This drug may temporarily cause dry mouth and can lead to visual disturbances, palpitations, and sensory abnormalities. Urinary difficulties, increased intraocular pressure, headache, dizziness, facial flushing, drowsiness, lethargy, constipation, nausea, and skin allergic reactions may occur. This drug may cause drowsiness, so driving or operating hazardous machinery should be avoided during treatment. The injection contains a certain amount of sodium, which should be noted. Concurrent use with other antihistamines, phenothiazine drugs, tricyclic antidepressants, and anticholinergic drugs may enhance the effects of this drug, so co-administration should be avoided. Conversely, parasympathomimetic agents may reduce the effects of this drug. Women who are pregnant or may become pregnant should use this drug cautiously as its safety has not been established, and it should be used only when necessary. The safety of this drug in children has not been sufficiently confirmed, especially in infants, where symptoms of central nervous system stimulation or respiratory issues may occur, requiring careful consideration. High doses may induce seizures, and concerns for habituation or dependency exist. In case of overdose, specific antidotes should be administered intramuscularly, and immediate medical attention is necessary. This drug should be stored out of the reach of children and care should be taken to avoid transferring it to other containers, as this may lead to quality degradation or accidental exposure.

• dry mouth
• visual disturbance
• palpitations
• sensory impairment
• urinary difficulty
• increased intraocular pressure
• headache
• dizziness
• facial flushing
• hyperhidrosis

This drug may be sensitive to light and should be stored in a container that does not allow light in. Additionally, it is best stored at room temperature, avoiding extremely hot or cold conditions.

Appearance

A brown ampoule containing a colorless and transparent liquid

Package unit

1mL x 50 ampoules